Finance da Vinci, ROSA, Mako, and other robotic surgery systems β $500K to $2.5M+.
No cost, no obligation, no credit impact.
Bank-level encryption. Your info is confidential.
Trusted by 1,000+ businesses nationwide
"I've worked with Brobas for a long time. They provided financing with a minimal down payment, which was crucial for me. Since then, I've grown with them and plan to open a fourth location."
Nikola T.
Fleet Owner
"The first day after submitting documents, they gave me a full breakdown of my situation and explained the strategy. I got a great offer, and now the truck works for me β not the other way around."
Oleh O.
Owner-Operator
"Brobas has great relationships with banks. The monthly payment they offered was comparable, if not lower, than equipment financing. You won't get the same terms walking into a street bank."
Natalya P.
Business Owner
Robotic surgery systems represent the cutting edge of surgical technology β and a major competitive advantage for hospitals and surgical centers. Whether you're acquiring an Intuitive da Vinci Xi for general and urological surgery, a Zimmer Biomet ROSA for orthopedic procedures, or a Stryker Mako for joint replacement, Brobas Capital Partners connects you with healthcare-specialized lenders who understand the revenue impact and clinical value of robotic surgery platforms.
Finance surgical robots from $500K to $2.5M+ with terms up to 84 months.
Lenders evaluate your surgical volume, case mix, and reimbursement rates β not just credit scores.
Bundle installation, surgeon training, service contracts, and instrument costs into financing.
Structured financing that allows technology upgrades as new robotic platforms are released.
Fill out a quick 5-minute application. No impact on your credit score.
Our AI engine matches you with the best lenders from our 500+ network.
Review competitive offers with transparent rates and terms.
Choose your best option and receive funding β often within days.
β’ $2,200,000 Intuitive da Vinci Xi System β Community hospital, 25 years operating, 760 credit. 5.24% APR, 84 months, 5% down. Includes installation, training, and first-year service contract.
β’ $950,000 Stryker Mako SmartRobotics β Orthopedic surgery center, 12 years, 730 credit. 5.49% APR, 72 months, $0 down.
β’ $1,500,000 da Vinci SP (Single-Port) β Multi-hospital system adding urology robotic program, 745 credit. 5.24% APR, 84 months, MLA structure.
β’ $650,000 Zimmer Biomet ROSA Knee β Orthopedic ASC, 8 years operating, 715 credit. 5.74% APR, 72 months, 10% down.
Surgeon Recruitment: Robotic capability is now a top-3 factor for surgeons choosing where to practice. Hospitals without robotics risk losing their best surgeons to competitors.
Patient Demand: Patients increasingly research and request robotic surgery. Hospitals with robotic programs report 20-40% increases in surgical volume from new patient acquisition.
Clinical Outcomes: Robotic surgery consistently demonstrates shorter hospital stays (1-2 fewer days), lower complication rates, less blood loss, and faster return to normal activity. These outcomes translate to better quality metrics, higher CMS ratings, and improved payer negotiations.
Financial Impact: While the upfront cost is significant, the revenue impact is substantial. A hospital performing 200 robotic cases/year at an average reimbursement premium of $3,000 per case generates $600,000 in incremental revenue. Combined with reduced length of stay and lower complication costs, most systems achieve positive ROI within 24-36 months.
The Intuitive da Vinci Xi system costs approximately $1.5M-$2.5M. The da Vinci SP (single-port) is approximately $1.5M-$2M. Annual service contracts add $150K-$200K. Per-case instrument costs are $700-$3,500 per procedure.
Hospitals performing 150+ robotic cases/year typically see positive ROI within 2-3 years. Robotic surgery reduces average length of stay by 1-2 days, reduces readmissions, and attracts higher-acuity cases. Many hospitals report surgical volume increases of 20-40% after adding robotic capability.
Yes. ASCs performing robotics is a growing trend, especially for urological and gynecological procedures. We have lenders experienced with ASC financing models and the unique revenue patterns of outpatient surgical facilities.
Absolutely. The Stryker Mako ($800K-$1.2M), Zimmer Biomet ROSA ($600K-$1M), and Smith+Nephew CORI ($400K-$700K) are all equipment types we frequently finance.
No cost, no obligation, no credit impact.
Bank-level encryption. Your info is confidential.